246 related articles for article (PubMed ID: 34531225)
21. Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study.
Li PC; Huang RY; Yang YC; Hsieh KP; Yang YH
BMC Cancer; 2022 Apr; 22(1):430. PubMed ID: 35443635
[TBL] [Abstract][Full Text] [Related]
22. An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes.
Kurdi A; Mueller T; Weir N
Eur J Clin Invest; 2023 Feb; 53(2):e13888. PubMed ID: 36205627
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
Tleyjeh IM; Bin Abdulhak AA; Tlayjeh H; Al-Mallah MH; Sohail MR; Hassett LC; Siller-Matula JM; Kashour T
Am J Ther; 2020 Dec; 29(1):e74-e84. PubMed ID: 33395057
[TBL] [Abstract][Full Text] [Related]
24. Renin-Angiotensin System Blocker in COVID-19. A Single Center Study.
Job R; Abdul Qader M; Torres P; Al Abbasi B; Dewaswala N; Abdallah A; Chen K; Pino JE; Chait RD
J Cardiovasc Pharmacol; 2022 Mar; 79(3):311-314. PubMed ID: 34861663
[TBL] [Abstract][Full Text] [Related]
25. Relation Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Severity.
Alhaddad MJ; Almulaify MS; Alshabib AA; Alwesaibi AA; Alkhameys MA; Alsenan ZK; Alsheef HJ; Alsaghirat MA; Almomtan MS; Alshakhs MN
Cureus; 2022 Mar; 14(3):e22903. PubMed ID: 35399441
[TBL] [Abstract][Full Text] [Related]
26. Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs.
Byttebier G; Belmans L; Alexander M; Saxberg BEH; De Spiegeleer B; De Spiegeleer A; Devreker N; Van Praet JT; Vanhove K; Reybrouck R; Wynendaele E; Fedson DS
Hum Vaccin Immunother; 2021 Sep; 17(9):2841-2850. PubMed ID: 34047686
[TBL] [Abstract][Full Text] [Related]
27. The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19.
Najafi N; Davoudi A; Izadyar H; Alishahi A; Mokhtariani A; Soleimanpourian B; Tabarrayi M; Moosazadeh M; Daftarian Z; Ahangarkani F
Ir J Med Sci; 2023 Jun; 192(3):1517-1523. PubMed ID: 35854192
[TBL] [Abstract][Full Text] [Related]
28. Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial.
Macedo AVS; de Barros E Silva PGM; de Paula TC; Moll-Bernardes RJ; Mendonça Dos Santos T; Mazza L; Feldman A; Arruda GDAS; de Albuquerque DC; de Sousa AS; de Souza OF; Gibson CM; Granger CB; Alexander JH; Lopes RD
Am Heart J; 2022 Jul; 249():86-97. PubMed ID: 35405099
[TBL] [Abstract][Full Text] [Related]
29. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
Georges JL; Gilles F; Cochet H; Bertrand A; De Tournemire M; Monguillon V; Pasqualini M; Prevot A; Roger G; Saba J; Soltani J; Koukabi-Fradelizi M; Beressi JP; Laureana C; Prost JF; Livarek B
PLoS One; 2020; 15(12):e0244349. PubMed ID: 33347477
[TBL] [Abstract][Full Text] [Related]
30. Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
Megaly M; Glogoza M
Scott Med J; 2020 Nov; 65(4):123-126. PubMed ID: 32807019
[TBL] [Abstract][Full Text] [Related]
31. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
32. Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Mortality in Patients with Hypertension Hospitalized with COVID-19.
Abedtash A; Taherkhani M; Shokrishakib S; Nikpour S; Taherkhani A
J Tehran Heart Cent; 2021 Jul; 16(3):95-101. PubMed ID: 35633826
[No Abstract] [Full Text] [Related]
33. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension.
Tian C; Li N; Bai Y; Xiao H; Li S; Ge QG; Shen N; Ma QB
World J Clin Cases; 2021 Jan; 9(1):47-60. PubMed ID: 33511171
[TBL] [Abstract][Full Text] [Related]
34. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
[TBL] [Abstract][Full Text] [Related]
35. Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury.
Suberviola B; Rodrigo E; González-Castro A; Serrano M; Heras M; Castellanos-Ortega Á
Med Intensiva; 2017; 41(1):21-27. PubMed ID: 28341094
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity.
Jaberi-Douraki M; Meyer E; Riviere J; Gedara NIM; Kawakami J; Wyckoff GJ; Xu X
Sci Rep; 2021 Jun; 11(1):13349. PubMed ID: 34172790
[TBL] [Abstract][Full Text] [Related]
37. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
[TBL] [Abstract][Full Text] [Related]
38. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
[TBL] [Abstract][Full Text] [Related]
39. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.
Soleimani A; Kazemian S; Karbalai Saleh S; Aminorroaya A; Shajari Z; Hadadi A; Talebpour M; Sadeghian H; Payandemehr P; Sotoodehnia M; Bahreini M; Najmeddin F; Heidarzadeh A; Zivari E; Ashraf H
Am J Hypertens; 2020 Dec; 33(12):1102-1111. PubMed ID: 32920644
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
Rizk JG; Wenziger C; Tran D; Hashemi L; Moradi H; Streja E; Ahluwalia A
Drugs; 2022 Jan; 82(1):43-54. PubMed ID: 34914085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
